Results of the Pharmaceutical Affairs Subcommittee Regarding the Application of Epogin for Chemotherapy-Induced Anemia
Chugai will consider future action regarding this indication for Epogin®.
There shall be no change in the outlook for fiscal year 2011, ending Dec. 31, 2011.
|Name of listed company:||Chugai Pharmaceutical Co., Ltd.|
|Code number:||4519 (1st Section of Tokyo Stock Exchange)|
|Head office:||1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo|
|President & CEO:||Osamu Nagayama|
General Manager, Corporate Communications Dept.
Posted: September 2011